title: [Efficacy and safety of bivalos therapy for postmenopausal osteoporosis. Results of Russian multicenter trial].
abstract: OBJECTIVE
  To study effects of one-year therapy with bivalos on mineral bone density (MBD) of the spine in patients with postmenopausal osteoporosis (PMO), effects of bivalos (strontium ranelate) on MBD of the neck of the femur and femur, the levels of bone metabolism markers, quality of life, tolerance of long-term therapy.
  
  
  METHODS
  The study was made of 60 females aged 54-75 years with PMO. MBD was measured with x-ray absorptiometry in the vertebra and proximal femur. Bone markers in blood serum were detected by enzyme immunoassay.
  
  
  RESULTS
  After a year of taking bivalos MBD in lumbar vertebra increased by 4.68 +/- 4.94%, in the neck of the femur--by 2.0 +/- 4.29%, in the proximal femur--by 3.10 +/- 3.34%. A significant 19.5% rise in bone alkaline phosphatase and a 16.5% fall in the level of CT were noted showing a stimulating effect of bivalos on bone formation and an inhibiting effect--on bone tissue resorption. Bivalos treatment raised quality of life of the patients: better motility, regress of depression, improved self-appraisal, decreased number of patients with pain in the spine, attenuated pain. The drug was well tolerated, unwanted effects arose in 15% patients, discontinuation of the drug because of toxicity occurred in 5%. Serious side effects were not observed.
  
  
  CONCLUSIONS
  Strontium ranelate is effective in PMO and is well tolerated.
authors.forename: L Ia
authors.initials: LIa
authors.lastname: Rozhinskaia
authors.forename: S D
authors.initials: SD
authors.lastname: Arapova
authors.forename: L K
authors.initials: LK
authors.lastname: Dzeranova
authors.forename: N N
authors.initials: NN
authors.lastname: Molitvoslovova
authors.forename: E I
authors.initials: EI
authors.lastname: Marova
authors.forename: A V
authors.initials: AV
authors.lastname: Il'in
authors.forename: L I
authors.initials: LI
authors.lastname: Benevolenskaia
authors.forename: O A
authors.initials: OA
authors.lastname: Nikitinskaia
authors.forename: T A
authors.initials: TA
authors.lastname: Korotkova
authors.forename: N V
authors.initials: NV
authors.lastname: Toroptsova
authors.forename: A V
authors.initials: AV
authors.lastname: Smirnov
authors.forename: N V
authors.initials: NV
authors.lastname: Demin
authors.forename: S S
authors.initials: SS
authors.lastname: Rodionova
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Buklemeshev
authors.forename: A A
authors.initials: AA
authors.lastname: Shumskiĭ
mesh_terms: D015502:Absorptiometry, Photon; D000284:Administration, Oral; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000378:metabolism; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D016207:Cytokines; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate